Oppenheimer's Top SMID Ideas Within High-growth Themes
Oppenheimer Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Raises Target Price to $104
Oppenheimer analyst Andreas Argyrides maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and adjusts the target price from $92 to $104.According to TipRanks data, the analyst has a su
Express News | MoonLake Immunotherapeutics : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $104
MoonLake Immunotherap Initiated at Outperform by Oppenheimer
MoonLake Immunotherap Initiated at Outperform by Oppenheimer
MoonLake Immunotherap Price Target Announced at $104.00/Share by Oppenheimer
MoonLake Immunotherap Price Target Announced at $104.00/Share by Oppenheimer
Oppenheimer Initiates Coverage On MoonLake With Outperform Rating, Announces Price Target of $104
Oppenheimer analyst Andreas Argyrides initiates coverage on MoonLake with a Outperform rating and announces Price Target of $104.
Psoriasis Market to Register Incremental Growth by 2034, Predicts DelveInsight | Key Companies - AnaptysBio, Nimbus Lakshmi, Takeda, MoonLake Immunotherapeutics, Bristol-Myers Squibb, Amgen, Dermavant Sciences
DelveInsight's analysts estimate that the psoriasis market is poised to show significant growth, mainly attributed to increasing prevalence, recent drug approvals, and anticipated launch of novel the
Komodo Health Introduces the First Integrated Patient Insurance Dataset to Enhance Patient-Level Insights for Life Sciences
Komodo Sets a New Industry Standard for Applying Real-World Data and Analytics to More Accurately Understand Patient Insurance Status at Both Regional and National LevelsSAN FRANCISCO--(BUSINESS WIRE)
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $100
H.C. Wainwright analyst Ram Selvaraju maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success r
BTIG Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $71
BTIG analyst Julian Harrison maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and maintains the target price at $71.According to TipRanks data, the analyst has a success rate of 49.
Needham Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $66
Needham analyst Serge Belanger maintains $MoonLake Immunotherapeutics(MLTX.US)$ with a buy rating, and maintains the target price at $66.According to TipRanks data, the analyst has a success rate of 4
MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham
MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham
Express News | Needham Reiterates Buy on MoonLake, Maintains $66 Price Target
Express News | MoonLake Immunotherapeutics Says FDA And EMA Both Unanimously Support Co.'s Proposed Approach For Advancing Its Phase 3 Program Of The Nanobody Sonelokimab In Psoriatic Arthritis
Express News | MoonLake Immunotherapeutics: First Patient Expected to Be Randomized in Q4 2024; Primary Endpoint Readout Expected End-2026
Express News | MoonLake Immunotherapeutics Announces Positive Regulatory Feedback From Both FDA and EMA on Path for the Phase 3 Program for the Nanobody® Sonelokimab in Psoriatic Arthritis
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Buy Rating Reaffirmed for MoonLake Immunotherapeutics Amidst Promising Clinical Trials and Strategic Development Plans
Express News | MoonLake Immunotherapeutics - Topline Primary Endpoint Readout at Week 16, Together With Data on Other Endpoints, Is Expected as of Mid-2025
Express News | MoonLake Immunotherapeutics Starts Phase 3 Vela Program of the Nanobody® Sonelokimab in Patients With Moderate-to-Severe Hidradenitis Suppurativa